Cardiff University Alumni Announce UK-India Strategic Partnership for Immunity Testing

Dr James Hindley CEO of ImmunoServ and Dr Sivasankar Baalasubramanian CEO and Founder of ImmunitasBio signing Strategic Partnership Agreement at St David’s Day Celebration in Mumbai, India

1st March 2023 on St David’s Day, ImmunoServ from Cardiff, Wales, UK signed a Strategic Partnership with ImmunitasBio of Bangalore, India to formalise its support for each other in their shared purpose in providing expert immunology products and services across the world.

Read More

ImmunoServ wins Judges Award at MediWales Innovation Awards

On Thursday 8th December MediWales held their seventeenth annual MediWales Innovation Awards in Cardiff. It was a fabulous evening celebrating collaboration and innovation across the Welsh life science and health and social care sectors. ImmunoServ were thrilled to win the prestigious Industry Judges Award.

Read More

COVID-19 Immuno-T™ T cell test grabs the headlines

Last month ImmunoServ’s latest research in collaboration with Cardiff University was published in the prestigious Nature Communications journal. The research is the culmination of many years research, devotion and hard work. We are especially grateful to all the volunteers who contributed to this work, as well as those who funded the work including UKRI, InnovateUK, and the National Core Studies.

Read More

Immuno-T COVID T Cell Test Now Available to Buy

Immuno-T - Covid T Cell Kit

At ImmunoServ we are on a mission to bring T cell testing to the masses. The World’s first At-Home COVID-19 T cell test is now available to anyone in the United Kingdom. People who wish to test their own T cell immune response to COVID-19 using Immuno-TTM, can visit our Immuno-T website.

Read More

Recruitment for At Home Immuno-T Validation Study Complete

In January 2022 ImmunoServ launched its trial of the Worlds first At-Home combined COVID-19 T cell and antibody test. Participants from across the UK were invited to sign up to the validation study. Within 10 weeks more than 300 participants have been recruited.

Read More

ImmunoServ Appoints New CEO

James Hindley

ImmunoServ is pleased to announce the appointment of Dr James Hindley as our new Chief Executive Officer. James brings a wealth of immunology and entrepreneurial experience in guiding biotech ventures; his proven leadership in the field is an excellent fit for ImmunoServ’s mission to provide expert immunology services to the world.

Read More

Omicron T cell test under development

Omicron T cell test under development

Following the WHOs announcement about the new SARS-CoV-2 Omicron variant of concern (VoC) on 26 November 2021, the team here at ImmunoServ have started working on a T cell immune response test for this variant. This rapid development demonstrates the flexibility of our T cell testing platform and the dedication of our company to help in the ongoing fight against COVID-19.

Read More